Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment

详细信息    查看全文

• 作者：Olga Kuzawińska^a ; ¹ ; Krzysztof Lis^a ; ¹ ; Grzegorz Cessak^a ; ^b ; Dagmara Mirowska-Guzel^a ; ^c ; Ewa Bałkowiec-Iskra^a ; ^b ; ^{ebalkowiec@wum.edu.pl" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Calcitonin gene-related peptide ; Migraine ; Monoclonal antibodies ; Calcitonin gene-related peptide antagonists
• 刊名：Neurologia i Neurochirurgia Polska
• 出版年：2016
• 出版时间：November-December 2016
• 年：2016
• 卷：50
• 期：6
• 页码：463-467
• 全文大小：353 K

文摘

Migraine is a chronic, recurrent disorder, characterized by attacks of severe pain, affecting around 1% of adult population. Many studies suggest, that trigeminovascular system plays a key role in pathogenesis of migraine and other primary headaches. Calcitonin gene-related peptide (CGRP) is an endogenous substance, which is regarded a key mediator released from trigeminovascular system after stimulation of sensory nerve endings, responsible for dilatation of peripheral vessels and sensory transmission. CGRP is and extensively studied peptide as one of the most promising targets in migraine drug research. In the article we focus on the role of CGRP in the pathophysiology of migraine and present current data on CGRP antagonists and CGRP monoclonal antibodies.